Cargando…

A Review of the Clinical Pharmacokinetics of Polymyxin B

Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avedissian, Sean N., Liu, Jiajun, Rhodes, Nathaniel J., Lee, Andrew, Pais, Gwendolyn M., Hauser, Alan R., Scheetz, Marc H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466567/ https://www.ncbi.nlm.nih.gov/pubmed/30909507 http://dx.doi.org/10.3390/antibiotics8010031

Ejemplares similares

1569. A Translational Model to Assess the Impact of Polymyxin B Dose Fractionation on Kidney Injury
por: Liu, Jiajun, et al.
Publicado: (2019)

1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
por: Liu, Jiajun, et al.
Publicado: (2018)

A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime
por: Avedissian, Sean N., et al.
Publicado: (2019)

1821. Understanding the Components and Calculation of the SAAR, Illustrative Data
por: Avedissian, Sean, et al.
Publicado: (2018)

1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury
por: Avedissian, Sean, et al.
Publicado: (2018)

1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies
por: Aljefri, Doaa, et al.
Publicado: (2018)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
por: Liu, Jiajun, et al.
Publicado: (2020)

Population pharmacokinetics of polymyxin B: a systematic review
por: Chen, Na, et al.
Publicado: (2022)

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
por: Hanafin, Patrick O., et al.
Publicado: (2021)

1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam
por: Pais, Gwendolyn M, et al.
Publicado: (2019)

1406. Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling with Bayesian Estimation in Children in the Pediatric Intensive Care Unit
por: Avedissian, Sean, et al.
Publicado: (2018)

Implementation of an Extended-Infusion Piperacillin-Tazobactam Dosing Protocol: Unexpected Findings when Monitoring Safety and Compliance with Smart Pump Technology
por: J. Rhodes, Nathaniel, et al.
Publicado: (2019)

Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures
por: Tam, Vincent H., et al.
Publicado: (2020)

Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy
por: Avedissian, Sean N., et al.
Publicado: (2021)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Iohexol-measured glomerular filtration rate and urinary biomarker changes between vancomycin and vancomycin plus piperacillin-tazobactam in a translational rat model
por: CHANG, Jack, et al.
Publicado: (2023)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
por: Liang, Danhong, et al.
Publicado: (2023)

Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study
por: Liu, Jiajun, et al.
Publicado: (2020)

1871. Identifying Time Periods of High and Low Vancomycin Use
por: Liu, Jiajun, et al.
Publicado: (2018)

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation
por: Zou, Dongna, et al.
Publicado: (2021)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models
por: van der Meijden, Aart, et al.
Publicado: (2023)

High‐Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin
por: Joshi, MD, et al.
Publicado: (2017)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

2000. Utilization of a ‘Never Event’ Framework to Classify Antimicrobial Appropriateness
por: Liu, Jiajun, et al.
Publicado: (2019)

Transcriptional responses of Burkholderia cenocepacia to polymyxin B in isogenic strains with diverse polymyxin B resistance phenotypes
por: Loutet, Slade A, et al.
Publicado: (2011)

Apheresis of activated leukocytes with an immobilized polymyxin B filter
por: Takeyama, N, et al.
Publicado: (2010)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Polymyxin B-Induced Skin Hyperpigmentation
por: Wen, Xueke, et al.
Publicado: (2020)

Colistin and polymyxin B: A re-emergence
por: Gupta, Sachin, et al.
Publicado: (2009)

Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
por: Liu, Li, et al.
Publicado: (2020)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

2946. Comparative Pharmacokinetics and Pharmacodynamics of Cefadroxil and Cephalexin for Pediatric Musculoskeletal Infections
por: Haynes, Andrew, et al.
Publicado: (2023)

Difficulty in detecting low levels of polymyxin resistance in clinical Klebsiella pneumoniae isolates: evaluation of Rapid Polymyxin NP test, Colispot Test and SuperPolymyxin medium
por: Conceição-Neto, O.C., et al.
Publicado: (2020)

Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms
por: Lu, Qiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gcjt4s6utlot6o3lv69obb8fjs